Predictors of Omalizumab non-response in ABPA and exploratory biomarkers for switching to mepolizumab: A retrospective cohort study
This retrospective cohort study of 63 ABPA patients identifies longer oral corticosteroid duration and the presence of mucous plugs as independent predictors of omalizumab non-response, while suggesting that elevated baseline FeNO and Aspergillus-specific IgE levels may indicate potential benefit from switching to mepolizumab.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Allergic bronchopulmonary aspergillosis, or ABPA, is a condition where the lungs overreact to a common mold called Aspergillus fumigatus. This mold is everywhere in the air, but for some people with severe asthma, breathing it in triggers a violent immune response. The body sends out an army of white blood cells and produces sticky mucus that clogs the airways, leading to chronic coughing, wheezing, and potentially permanent lung damage. For decades, the main way to calm this inflammation has been oral corticosteroids, strong medicines that suppress the immune system. However, these drugs come with heavy side effects, and many patients find they cannot stop taking them without their symptoms flaring back up. In recent years, doctors have turned to a newer class of drugs called biologics. These are laboratory-made proteins designed to block specific parts of the immune system. Two of the most common ones are omalizumab, which targets a molecule called IgE, and mepolizumab, which targets a different pathway involving white blood cells known as eosinophils. The challenge for doctors has been figuring out which drug will work for which patient, as the immune systems of people with ABPA vary widely.
Researchers at Beijing Chaoyang Hospital set out to solve this puzzle by looking back at the medical records of 63 adults with ABPA who had been treated with omalizumab between 2016 and 2025. They wanted to find out why the drug worked for some patients but failed for others, and whether there were clues in a patient's initial health profile that could predict who would need to switch to a different drug, mepolizumab, instead. The team divided the patients into two groups: those who responded well to omalizumab, meaning they could significantly reduce their steroid use and stay symptom-free, and those who did not respond, meaning their symptoms persisted or their steroid needs remained high.
The study revealed that the patients who did not respond to omalizumab shared a distinct set of characteristics. They tended to have a shorter history of symptoms before starting treatment, suggesting their disease might be more aggressive from the start. More importantly, these non-responders had higher levels of a specific type of white blood cell called eosinophils and higher levels of a gas in their breath called nitric oxide, both of which are markers of intense inflammation. The most striking difference, however, was found in their lung scans. Patients who failed to respond to omalizumab were much more likely to have visible mucus plugs—thick, sticky blocks of mucus lodged deep in the airways. The researchers found that the presence of these plugs and a longer history of taking oral steroids before starting the biologic were the strongest independent predictors that omalizumab would not work. In essence, the physical blockage of mucus and the depth of prior steroid dependence seemed to shield the disease from the effects of the anti-IgE drug.
For the patients who did not respond to omalizumab, the researchers looked at a smaller group of 13 individuals who were switched to mepolizumab and subsequently improved. This group offered a different set of clues. These patients were generally younger and had started treatment sooner after their symptoms began. Their blood tests showed extremely high levels of total IgE, specific IgE against the mold, eosinophils, and nitric oxide. By analyzing these numbers, the researchers identified specific thresholds that might help doctors decide when to skip omalizumab entirely and go straight to mepolizumab. They found that patients with a breath nitric oxide level above 47.5 parts per billion and a specific mold antibody level above 6.995 units per liter were strong candidates for the alternative drug.
The authors are careful to note that these specific numbers for switching drugs are preliminary. Because the group of patients who switched to mepolizumab was small, these findings are best viewed as a hypothesis to be tested in larger studies rather than a final rule for clinical practice. However, the findings regarding omalizumab failure are robust. The study confirms that if a patient has visible mucus plugs on a CT scan or has been on oral steroids for a long time, omalizumab is less likely to succeed. For these patients, the physical barrier of the mucus may prevent the drug from reaching its target, much like a thick fog obscuring a lighthouse beam. This insight allows doctors to identify high-risk patients early and consider alternative strategies, potentially sparing them from months of ineffective treatment and prolonged steroid use. The study ultimately provides a clearer map for navigating the complex landscape of ABPA treatment, suggesting that looking at the specific type of inflammation and the physical state of the airways can guide the choice of life-changing biologic therapies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.